Journal of Diabetes & Clinical Practice
Open Access

Sleep disorders; Diabetes mellitus; Glycemic control; Obstructive sleep apnea; Insomnia; Restless legs syndrome; Integrated care; Multidisciplinary approach

Introduction

Sleep plays a crucial role in regulating metabolic processes, including glucose metabolism, insulin sensitivity, and appetite regulation. Sleep disorders, such as obstructive sleep apnea (OSA), insomnia, and restless legs syndrome (RLS), are common among individuals with diabetes and can exacerbate metabolic dysfunction, contributing to poor glycemic control and increased cardiovascular risk. Understanding the impact of sleep disorders on diabetes management is essential for optimizing patient care and improving health outcomes [1,2].

Methodology

Mechanisms linking sleep disorders and diabetes: Several mechanisms have been proposed to explain the bidirectional relationship between sleep disorders and diabetes. Disrupted sleep patterns and sleep fragmentation can lead to alterations in neuroendocrine function, including dysregulation of cortisol, growth hormone, and leptin levels, which may contribute to insulin resistance and impaired glucose tolerance. Additionally, sleep disturbances can trigger systemic inflammation, oxidative stress, and sympathetic nervous system activation, further exacerbating metabolic dysfunction and insulin resistance [3,4].

Impact of sleep disorders on glycemic control: Poor sleep quality and insufficient sleep duration have been associated with worsened glycemic control and increased risk of developing diabetes complications. Individuals with diabetes and comorbid sleep disorders are more likely to experience nocturnal hypoglycemia, morning hyperglycemia, and glycemic variability, posing challenges for diabetes management and treatment adherence. Furthermore, sleep disturbances can disrupt circadian rhythm regulation, impairing insulin secretion and glucose tolerance, and contributing to the development of insulin resistance and beta-cell dysfunction over time [5,6].

Screening and diagnosis of sleep disorders in diabetes: Given the high prevalence of sleep disorders among individuals with diabetes, routine screening and assessment for sleep disturbances are recommended as part of comprehensive diabetes care. Screening tools, such as the Berlin Questionnaire for OSA and the Insomnia Severity Index for insomnia, can help identify individuals at risk for sleep disorders and guide further evaluation and management. Polysomnography and home sleep apnea testing are the gold standard diagnostic tests for OSA, while subjective measures, such as sleep diaries and actigraphy, may be used to assess sleep quality and duration [7].

Management strategies for sleep disorders in diabetes: Management of sleep disorders in individuals with diabetes requires a multidisciplinary approach, addressing both diabetes-specific and sleep-related interventions. Lifestyle modifications, such as maintaining a regular sleep schedule, practicing good sleep hygiene, and avoiding stimulants before bedtime, are essential for improving sleep quality and duration. Continuous positive airway pressure (CPAP) therapy is the first-line treatment for OSA and has been shown to improve glycemic control and insulin sensitivity in individuals with diabetes. Cognitive-behavioral therapy for insomnia (CBT-I) is effective for treating insomnia and may complement diabetes management by addressing sleep-related behavioral and cognitive factors [8].

Integrated care approaches: Integrated care models that address both diabetes and sleep disorders simultaneously are essential for optimizing patient outcomes and improving quality of life. Collaboration between primary care providers, endocrinologists, sleep specialists, and allied health professionals can facilitate comprehensive assessment, personalized treatment planning, and ongoing monitoring of individuals with diabetes and comorbid sleep disorders. Future research efforts should focus on elucidating the underlying mechanisms linking sleep disturbances and diabetes, identifying novel therapeutic targets, and evaluating the impact of integrated care interventions on diabetes outcomes and long-term health [9,10].

Discussion

Future research efforts should focus on elucidating the underlying mechanisms linking sleep disturbances and diabetes, identifying novel therapeutic targets, and evaluating the impact of integrated care interventions on diabetes outcomes and long-term health. Longitudinal studies are needed to assess the effectiveness of sleep disorder management strategies in improving glycemic control, reducing diabetes-related complications, and enhancing quality of life in individuals with diabetes. Additionally, efforts to raise awareness among healthcare providers and promote routine screening for sleep disorders in individuals with diabetes are essential for improving diagnosis rates and access to appropriate treatment.

In conclusion, exploring the impact of sleep disorders on diabetes management highlights the importance of addressing sleep disturbances as part of comprehensive diabetes care. By recognizing the bidirectional relationship between sleep disorders and diabetes and implementing integrated care approaches, healthcare providers can optimize glycemic control, reduce the risk of complications, and improve quality of life for individuals living with diabetes.

Conclusion

Sleep disorders are common among individuals with diabetes and can have a profound impact on glycemic control, insulin sensitivity, and overall health outcomes. Recognizing the bidirectional relationship between sleep disturbances and diabetes is essential for optimizing diabetes management and improving quality of life. Integrated care approaches that address both diabetes and sleep disorders are warranted to provide comprehensive care and support for individuals with diabetes, ultimately reducing the burden of diabetes-related complications and improving long-term health outcomes.

1. Sayin N, Kara N, Pekel G (2015) Ocular complications of diabetes mellitus. World J Diabetes; 6: 92-108

Indexed at, Google Scholar, Crossref

2. Yau JWY, Rogers SL, Kawasaki R (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35: 556-564.

Indexed at, Google Scholar, Crossref

3. Vujosevic S, Aldington SJ, Silva P, Hernández C, Scanlon P, et al. (2020) Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol 8: 337-347

Indexed at, Google Scholar, Crossref

4. Duh EJ (2017) Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2: 93751.

Indexed at, Google Scholar, Crossref

5. Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group (2016) Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care 39: 1089-1100.

Indexed at, Google Scholar, Crossref

6. Chew EY, Davis MD, Danis RP (2014) Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 121: 2443-2451.

Indexed at, Google Scholar, Crossref

7. Chew EY, Ambrosius WT, Davis MD, Danis RP (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363: 233-244.

Indexed at, Google Scholar, Crossref

8. Zheng Y, He M, Congdon N (2012) The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol 60: 428-431.

Indexed at, Google Scholar, Crossref

9. Lu J, Ma X, Zhou J (2018) Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care 41: 2370-2376.

Indexed at, Google Scholar, Crossref

10. Zhao Q, Zhou F, Zhang Y, Zhou X, Ying C, et al. (2019) Fasting plasma glucose variability levels and risk of adverse outcomes among patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 148: 23-31.

Indexed at, Google Scholar, Crossref